Translating the BDI and BDI-II into the HAMD and vice versa with equipercentile linking.


Journal

Epidemiology and psychiatric sciences
ISSN: 2045-7979
Titre abrégé: Epidemiol Psychiatr Sci
Pays: England
ID NLM: 101561091

Informations de publication

Date de publication:
14 Mar 2019
Historique:
pubmed: 15 3 2019
medline: 22 5 2020
entrez: 15 3 2019
Statut: epublish

Résumé

The Hamilton Depression Rating Scale (HAMD) and the Beck Depression Inventory (BDI) are the most frequently used observer-rated and self-report scales of depression, respectively. It is important to know what a given total score or a change score from baseline on one scale means in relation to the other scale. We obtained individual participant data from the randomised controlled trials of psychological and pharmacological treatments for major depressive disorders. We then identified corresponding scores of the HAMD and the BDI (369 patients from seven trials) or the BDI-II (683 patients from another seven trials) using the equipercentile linking method. The HAMD total scores of 10, 20 and 30 corresponded approximately with the BDI scores of 10, 27 and 42 or with the BDI-II scores of 13, 32 and 50. The HAMD change scores of -20 and -10 with the BDI of -29 and -15 and with the BDI-II of -35 and -16. The results can help clinicians interpret the HAMD or BDI scores of their patients in a more versatile manner and also help clinicians and researchers evaluate such scores reported in the literature or the database, when scores on only one of these scales are provided. We present a conversion table for future research.

Identifiants

pubmed: 30867082
pii: S2045796019000088
doi: 10.1017/S2045796019000088
pmc: PMC8061209
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e24

Références

Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
J Consult Clin Psychol. 2001 Dec;69(6):942-9
pubmed: 11777121
Am J Psychiatry. 1999 Feb;156(2):202-8
pubmed: 9989555
Neuropsychopharmacology. 2000 Jun;22(6):559-65
pubmed: 10788756
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
Lancet. 2018 Apr 7;391(10128):1357-1366
pubmed: 29477251
J Psychiatr Res. 2013 Jul;47(7):944-54
pubmed: 23562150
J Consult Clin Psychol. 2006 Aug;74(4):658-70
pubmed: 16881773
PLoS Med. 2013;10(5):e1001454
pubmed: 23723742
Int J Neuropsychopharmacol. 2010 Feb;13(1):31-44
pubmed: 19341510
BMJ. 2013 Feb 26;346:f540
pubmed: 23444423
Psychopathology. 2007;40(3):147-52
pubmed: 17318006
Psychother Psychosom. 2018;87(3):140-153
pubmed: 29847831
J Consult Clin Psychol. 2009 Dec;77(6):1078-88
pubmed: 19968384
Biol Psychiatry. 2003 Sep 1;54(5):573-83
pubmed: 12946886
Schizophr Res. 2013 Apr;145(1-3):125-7
pubmed: 23394742
J Affect Disord. 2013 Jun;148(2-3):243-8
pubmed: 23357658
Arch Gen Psychiatry. 2005 Apr;62(4):409-16
pubmed: 15809408
Arch Gen Psychiatry. 1992 Oct;49(10):774-81
pubmed: 1417429
JAMA Psychiatry. 2017 Apr 1;74(4):351-359
pubmed: 28241179
Int Clin Psychopharmacol. 2008 May;23(3):120-9
pubmed: 18408526
Neuropsychopharmacology. 2006 Oct;31(10):2318-25
pubmed: 16823384
Psychiatry Res. 2011 Aug 30;189(1):1-9
pubmed: 21276619
BMC Psychiatry. 2008 May 16;8:36
pubmed: 18485191
Depress Anxiety. 2009;26(10):922-9
pubmed: 19006198
Arch Gen Psychiatry. 1984 Jan;41(1):33-41
pubmed: 6691783
J Affect Disord. 2018 Jan 15;226:326-331
pubmed: 29031182
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Br J Psychiatry. 2017 Mar;210(3):190-196
pubmed: 28104735
Schizophr Res. 2005 Nov 15;79(2-3):231-8
pubmed: 15982856
Arch Gen Psychiatry. 1999 May;56(5):431-7
pubmed: 10232298
BMJ Open. 2017 Feb 13;7(2):e013478
pubmed: 28193851
Arch Gen Psychiatry. 1989 Nov;46(11):971-82; discussion 983
pubmed: 2684085
Eur Neuropsychopharmacol. 2014 Nov;24(11):1767-72
pubmed: 25219937
J Affect Disord. 2017 Mar 01;210:287-293
pubmed: 28068617
Eur Neuropsychopharmacol. 2013 Aug;23(8):956-9
pubmed: 23433639
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
JAMA. 2007 Jan 24;297(4):367-79
pubmed: 17244833

Auteurs

Toshi A Furukawa (TA)

Departments of Health Promotion and Human Behavior and of Clinical Epidemiology, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan.

Mirjam Reijnders (M)

Department of Clinical, Neuro-, and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, The Netherlands.

Sanae Kishimoto (S)

Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan.

Masatsugu Sakata (M)

Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan.

Robert J DeRubeis (RJ)

Department of Psychology, University of Pennsylvania, Philadelphia, PA, USA.

Sona Dimidjian (S)

Department of Psychology and Neuroscience, University of Colorado, Boulder, USA.

David J A Dozois (DJA)

Department of Psychology, University of Western Ontario, Westminster Hall, London, Ontario N6A 3K7, Canada.

Ulrich Hegerl (U)

Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany.

Steven D Hollon (SD)

Department of Psychology, Vanderbilt University, Nashville, TN, USA.

Robin B Jarrett (RB)

Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.

François Lespérance (F)

Department of Psychiatry and Addiction, Université de Montréal, Montréal, Québec, Canada.

Zindel V Segal (ZV)

Department of Psychology, University of Toronto - Scarborough, Toronto, Canada.

David C Mohr (DC)

Center for Behavioral Intervention Technologies, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Anne D Simons (AD)

Department of Psychology, University of Oregon, Eugene, OR, USA.

Lena C Quilty (LC)

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health; Department of Psychiatry, University of Toronto, Toronto, Canada.

Charles F Reynolds (CF)

Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, Pittsburgh, USA.

Claudio Gentili (C)

Department of General Psychology, University of Padova, Padova, Italy.

Stefan Leucht (S)

Department of Psychiatry and Psychotherapy, Technische Universität München, Kkinikum rechts der Isar, Germany.

Rolf R Engel (RR)

Department of Psychiatry and Psychotherapy, Ludwig-Maximillians Universität München, Germany.

Pim Cuijpers (P)

Department of Clinical, Neuro-, and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH